Amgen Successfully Defeats Complex Innovations’ Challenge
On April 13, 2016, Fitzpatrick succeeded in obtaining a Decision Denying Institution of Inter Partes Review of Amgen’s U.S. Patent No. 7,829,595. Amgen’s patent relates to pharmaceutical compositions containing the active ingredient cinacalcet, which is useful in treating patients with hyperparathyroidism. The PTAB agreed with Fitzpatrick’s arguments that Complex Innovations had failed to make a showing of obviousness of the claimed composition.
The Fitzpatrick attorneys representing Amgen are John Murnane, Alicia Russo, Justin J. Oliver, and Rosanna Gan.